Home Blog of Signal Transduction GPCR & G Protein S1P Receptor

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

S1P Receptor

Blocking SphK/S1P/S1PR1 axis signaling pathway alleviates remifentanil-induced hyperalgesia in rats

51 views | Jan 19 2024

This study demonstrates that blocking the SphK/S1P/S1PR1 axis mitigates remifentanil-induced hyperalgesia by reducing spinal cord inflammation and reactive oxygen species, offering potential avenues for managing opioid-induced pain sensitization. [Read the Full Post]

Myeloid-derived growth factor suppresses VSMC dedifferentiation and attenuates postinjury neointimal formation in rats by activating S1PR2 and its downstream signaling

49 views | Nov 20 2023

The study demonstrates that Myeloid-derived growth factor (MYDGF) alleviates neointimal formation in rat carotid arteries post balloon injury by inhibiting vascular smooth muscle cell dedifferentiation through the S1PR2-RhoA-G/F-actin-MRTF-A signaling pathway, suggesting its potential as a therapeutic target for preventing restenosis after angioplasty. [Read the Full Post]

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

68 views | Jul 24 2023

The analysis comparing Diroximel fumarate (DRF) to Ponesimod (PON) and Teriflunomide (TERI) in the treatment of relapsing multiple sclerosis did not find strong evidence of differences in most clinical and radiological outcomes between DRF and PON, but showed improved efficacy of DRF compared to TERI for all outcomes except absence of new/newly enlarging T2 lesions. [Read the Full Post]

Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis

61 views | Jul 07 2023

Multiple sclerosis (MS) is a neurological disease where immune-mediated damage to the central nervous system (CNS) occurs, and while disease-modifying therapies primarily target immunomodulation, sphingosine 1-phosphate receptor (S1PR) modulators like fingolimod also exhibit direct effects on the CNS, potentially reducing neurodegenerative consequences. [Read the Full Post]

Identifying a selective inhibitor of autophagy that targets ATG12-ATG3 protein-protein interaction

132 views | Jun 29 2023

Compound 189, identified through a high throughput compound screen, selectively inhibits the ATG12-ATG3 protein-protein interaction involved in autophagy, demonstrating potential as a therapeutic drug for autophagy-dependent tumors and inflammation. [Read the Full Post]

The effect of sex on retinopathy of prematurity severity among premature mixed-sex multiple gestation infants

110 views | Jun 29 2023

This retrospective study of 68 premature infants found no significant difference between male and female mixed-sex multiple gestation infants in terms of the most severe stage of retinopathy of prematurity (ROP) developed or the need for ROP treatment, but males received treatment at an earlier postmenstrual age (PMA) despite females having lower birthweight and slower growth velocity. [Read the Full Post]

Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies

44 views | May 28 2023

The study uses a Xenopus laevis transgenic model of conditional demyelination to test candidate molecules for promoting remyelination, correlating functional and clinical performance measures with histopathological parameters to identify potential therapies. [Read the Full Post]

Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?

0 views | May 28 2023

Recent studies suggest that the FDA-approved drug fingolimod, which binds to sphingosine-1-phosphate receptors and was originally approved for multiple sclerosis, could potentially reverse synaptic deficits and memory dysfunction in Alzheimer's disease mouse models even when treatment is started after onset of symptoms. [Read the Full Post]

Insulin can up-regulate LC-PUFA biosynthesis with the involvement of Srebp-1c and stimulatory protein 1 (Sp1) in marine teleost Siganus canaliculatus

69 views | May 07 2023

The study found that insulin up-regulates long-chain polyunsaturated fatty acid biosynthesis in rabbitfish through the involvement of transcription factors Srebp-1c and Sp1, as demonstrated in a hepatocyte cell line. [Read the Full Post]

Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?

51 views | Apr 30 2023

FTY720, an FDA-approved drug for the treatment of multiple sclerosis, shows promise in reversing synaptic deficits and memory dysfunction in Alzheimer's disease mouse models, and could be a potential disease modifying anti-AD drug. [Read the Full Post]